Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    Ox40
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
Condition: Advanced Cancer.
Interventions: Drug: Cohort 1 anti-OX40;   Drug: Cohort 2 anti-OX40;   Drug: Cohort 3 anti-OX40;   Biological: Tetanus Day 29;   Biological: Tetanus Day 1;   Biological: KLH Day 1;   Biological: KLH Day 29
2 Withdrawn Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Anti-OX40;   Drug: Ipilimumab
3 Completed A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Condition: Asthma
Interventions: Drug: huMAb OX40L;   Drug: placebo
4 Recruiting Anti-OX40 Antibody in Head and Neck Cancer Patients
Condition: Head and Neck Cancer
Interventions: Drug: Anti-OX40 antibody administration;   Procedure: Surgical Resection
5 Recruiting Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
Conditions: Metastatic Breast Cancer;   Lung Metastases;   Liver Metastases
Intervention: Biological: MEDI6469
6 Active, not recruiting Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Cancer of the Prostate;   Prostate Cancer
Interventions: Drug: Anti-OX40;   Radiation: Radiation;   Drug: Cyclophosphamide
7 Recruiting Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: MEDI6469
8 Completed OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Condition: Cancer
Interventions: Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
9 Withdrawn Study of Immune Responses in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Biological: anti-OX40
10 Recruiting Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Condition: Neoplasms
Interventions: Drug: PF-04518600;   Drug: PF-04518600 plus PF-05082566
11 Recruiting Vasculopathy, Inflammation and Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Biological: Blood samples;   Biological: Biopsy
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: Fludarabine;   Genetic: GINAKIT Cells
13 Unknown  Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.
Condition: Critical Ill Patients in SICU
Intervention: Drug: Omegaven 10%
14 Not yet recruiting Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
Condition: Rabies
Intervention: Biological: rabies vaccine
15 Recruiting Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Conditions: Ulcerative Colitis;   Digestive System Diseases;   Colitis, Ulcerative;   Colitis;   Gastrointestinal Diseases;   Inflammatory Bowel Diseases;   Intestinal Diseases;   Colonic Diseases;   Autoimmune Disease;   Abdominal Pain
Interventions: Drug: KHK4083;   Drug: Placebo
16 Recruiting A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody;   Drug: Bevacizumab, a recombinant humanised anti-VEGF (vascular endothelial growth factor) monoclonal antibody;   Drug: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
17 Not yet recruiting A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Conditions: Advanced Cancer;   Metastatic Cancer
Intervention: Drug: INCAGN01949
18 Recruiting A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Condition: Select Advanced Solid Tumors
Interventions: Biological: MEDI0562;   Biological: Tremelimumab;   Biological: Durvalumab
19 Completed A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Conditions: Advanced Solid Tumors;   Aggressive B-cell Lymphomas
Interventions: Biological: MEDI6469/tremelimumab;   Biological: MEDI6469/MEDI4736;   Biological: MEDI6469/rituximab;   Biological: MEDI6469
20 Active, not recruiting A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Condition: Recurrent or Metastatic Solid Tumors
Interventions: Biological: MEDI6383;   Biological: MEDI6383 and MEDI4736

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years